Glaxosmithkline

This study tests a new drug called bepirovirsen in about 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can achieve a functional cure, meaning the virus is suppressed and no longer detectable after stopping al…

This study tests a new vaccine designed to prevent invasive nontyphoidal Salmonella (iNTS) infections, a major cause of severe illness and death in Africa, especially in young children. The trial involves 215 participants in Ghana, starting with adults, then children, and finally…

This study tests a new vaccine called Pn-MAPS30plus that may protect against more types of pneumonia bacteria than current vaccines. It involves 127 healthy adults aged 50 to 64. The main goal is to check if the vaccine is safe and helps the body build a strong immune defense.

This early-stage study tests an experimental mRNA vaccine designed to protect against respiratory syncytial virus (RSV). Around 213 healthy adults aged 18-45 will receive different doses of the vaccine or a placebo. The main goals are to check for side effects and measure the bod…

This study is testing a new vaccine called MenABCWY that protects against five groups of bacteria that cause meningitis, a serious infection around the brain and spine. About 312 healthy teenagers will receive the vaccine on different schedules to see how safe it is and how well …

This study tests new mRNA-based flu vaccines in 776 healthy adults aged 18 and older. The goal is to see how well the vaccines trigger an immune response and whether they are safe. Participants will be monitored for side effects like pain, fever, and fatigue. The results will hel…

This study looks at how well a meningitis B vaccine works and how safe it is for healthy babies starting at 2 months old in South Korea. About 50 infants will receive two initial doses and one booster shot. Researchers will measure the immune response and watch for any side effec…

This study looks at over 10,000 adults aged 60 and older who already received either an RSV vaccine or a placebo in a previous study. Researchers want to find the best timing for a booster shot and see how long protection lasts over five RSV seasons. Participants who got a placeb…

This study tests new mRNA-based seasonal flu vaccines in about 971 healthy adults aged 18 and older. The goal is to see how safe the vaccines are and how well they boost the immune system against flu. Researchers will measure antibody levels and track any side effects like pain, …

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses to find the best vacc…

This study tests an experimental pill (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug targets a DNA repair protein to try to shrink tumors. The trial will check safety, side effects, and how well the drug works alone …

This study tests an experimental drug, GSK4532990, to see if it can improve liver scarring and inflammation in people with nonalcoholic steatohepatitis (NASH) who already have advanced fibrosis. About 284 adults will receive either the drug or a placebo for up to 52 weeks. The go…

This study tests an experimental drug called GSK4527226 in 367 people with early Alzheimer's (mild memory problems or mild dementia). Participants receive either a low dose, high dose, or placebo as an IV infusion. The goal is to see if the drug can slow down worsening of memory …

This phase 3 study tests whether a new combination of drugs (belantamab mafodotin, bortezomib, and dexamethasone) works better than the current standard (daratumumab, bortezomib, and dexamethasone) for Japanese patients whose multiple myeloma has returned or stopped responding to…

This study tests whether adding two immunotherapy drugs (cobolimab and dostarlimab) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The trial includes about 758 adults whose cancer worsened after prior chemotherapy and immun…

This Phase 3 trial compares two drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 494 participants receive either a new drug (belantamab mafodotin) plus standard drugs, or another approved combination. The goal is to s…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of two drugs: belantamab mafodotin and nirogacestat. The goal is to find the safest dose and see how well the combination controls th…

This study tests a new medicine, GSK5784283, for adults aged 18 to 75 whose asthma is not well controlled despite regular treatments. The drug blocks a protein called TSLP that may cause inflammation. The trial has two parts: first to find the best dose by checking lung function …

This study tests whether combining different immunotherapy drugs can shrink tumors better than one drug alone in people with a type of head and neck cancer that has come back or spread. It includes 316 adults whose cancer has a specific marker (PD-L1 positive) and who have not ha…

This study tests a combination of two drugs, belantamab mafodotin and isatuximab, in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to find a safe dose and see how well the combo shrinks tumors. About 30 adult…

This phase 3 study tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to t…

This study tests a drug called belantamab mafodotin, alone or with other cancer drugs, in people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The drug targets a protein on myeloma cells to deliver a toxin directly. The trial aims t…

This study tests whether a new triple-combination inhaler (FF/UMEC/VI) works better than the usual two-medication inhaler (ICS/LABA) for adults whose asthma is not well controlled. About 1,366 participants will use one of the two treatments for 24 weeks, and researchers will meas…

This early-phase study tests a new experimental drug called GSK6097608, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 107 adults will take pa…

This study tests a new oral drug (GSK4524101) alone and with another drug (niraparib) in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 42 participants will …

This study was designed to see how the drug belantamab mafodotin works in people with relapsed or refractory multiple myeloma who also have liver problems. It aimed to compare drug levels and safety between patients with normal and impaired liver function. However, the study was …

This study tests a new drug called belantamab mafodotin against a standard combination therapy (pomalidomide plus dexamethasone) in people with multiple myeloma that has returned or stopped responding to prior treatments. About 325 adults will be randomly assigned to receive eith…

This study tests whether the immunotherapy drug dostarlimab alone can effectively treat people with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. About 154 participants will receive dostarlimab and be closely monitored. The goal is to se…

This early-stage study tests a new drug called belantamab mafodotin combined with standard treatments (bortezomib, lenalidomide, dexamethasone) in adults newly diagnosed with multiple myeloma. The goal is to find the safest and most effective dosing schedule. About 118 participan…

This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The …

This study tests a new combination of two drugs (belrestotug and dostarlimab) against the current standard treatment (pembrolizumab) in people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combo is safer and works better.…

This study gives people with myelofibrosis continued access to the drug momelotinib after they finish a previous trial. The goal is to monitor long-term safety and see how long patients live. About 237 adults who are already taking momelotinib without their disease getting worse …

This study tests a drug called dostarlimab in 23 Chinese patients with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. The goal is to see if the drug can make the cancer disappear completely and stay gone for at least 12 months. Patients r…

This study tests a combination of two drugs, belantamab mafodotin and feladilimab, in about 25 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goals are to check safety and find the best dose. This is not a cure, …

This study tests whether the drug bepirovirsen can help control hepatitis B in people who also have HIV and are already on stable HIV treatment. About 153 participants will receive either bepirovirsen or a placebo, and researchers will check if the hepatitis B virus becomes undet…

This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to see how the drug behaves in the body and if it is safe when used with standard treatments. About 25 children will take part, and the study lasts 68 weeks.

This early-stage study tests a new drug called remzistotug in 152 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to check the drug's safety and how the body processes it, both alone and with other cancer drugs. Participants must…

This study tests a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to find the safest dose and see how well the comb…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how well …

This early-phase study tests a new experimental drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effec…

This study is testing new combinations of immunotherapy drugs in people with advanced non-small cell lung cancer that has not been treated before. Participants must have high levels of a protein called PD-L1 on their tumors. The main goal is to check the safety of these drug comb…

This study compares a new drug, depemokimab, to an existing one, mepolizumab, in adults with a rare inflammatory disease called EGPA. The goal is to see if depemokimab can help patients achieve and maintain remission (no symptoms and low steroid use) over 52 weeks. Participants m…

This study looks at the long-term safety of the drug linerixibat for treating severe itching caused by primary biliary cholangitis (PBC), a chronic liver disease. About 242 adults who previously took linerixibat in earlier studies will continue receiving the drug. The goal is to …

This study looks at the safety of the shingles vaccine (HZ/su) in pregnant women aged 18-49 with weakened immune systems. Researchers will compare rates of major birth defects and other infant health problems between vaccinated and unvaccinated women. The goal is to gather real-w…

This study is the first time the experimental drug GSK4347859 is given to humans. It aims to check the drug's safety and how it behaves in the body, not to treat any disease. About 65 healthy adults will receive either the drug or a placebo. The trial is currently on hold.

This study is the first time GSK4528287, a drug for inflammatory bowel diseases like ulcerative colitis, is given to humans. It involves 48 healthy volunteers who receive a single dose to check for side effects, measure drug levels in the blood, and see how the drug works in the …